HC Wainwright Issues Negative Estimate for Absci Earnings

Absci Co. (NASDAQ:ABSI - Free Report) - Research analysts at HC Wainwright dropped their Q1 2025 EPS estimates for Absci in a research report issued on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.27) for the quarter, down from their prior forecast of ($0.19). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Absci's current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Absci's Q2 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.31) EPS, FY2028 earnings at $0.20 EPS and FY2029 earnings at ($0.02) EPS.

Absci (NASDAQ:ABSI - Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.03). The business had revenue of $0.67 million for the quarter, compared to the consensus estimate of $1.77 million. Absci had a negative return on equity of 46.56% and a negative net margin of 2,321.56%.

ABSI has been the topic of a number of other reports. KeyCorp lowered their target price on shares of Absci from $6.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Needham & Company LLC restated a "buy" rating and set a $9.00 price objective on shares of Absci in a research note on Wednesday, March 19th. Finally, Guggenheim reiterated a "buy" rating and issued a $10.00 target price on shares of Absci in a research note on Thursday, March 20th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $8.57.

Remove Ads

Absci Stock Down 1.0 %

Shares of Absci stock traded down $0.03 on Friday, reaching $3.07. 2,506,171 shares of the company were exchanged, compared to its average volume of 2,400,846. The company has a market capitalization of $390.92 million, a price-to-earnings ratio of -3.30 and a beta of 2.09. The company has a current ratio of 5.63, a quick ratio of 5.63 and a debt-to-equity ratio of 0.01. Absci has a one year low of $2.45 and a one year high of $6.72. The company has a 50-day moving average of $3.88 and a 200 day moving average of $3.64.

Institutional Trading of Absci

Several hedge funds and other institutional investors have recently modified their holdings of the stock. PCA Investment Advisory Services Inc. acquired a new stake in Absci during the fourth quarter worth approximately $26,000. Alpha Cubed Investments LLC acquired a new stake in Absci during the 4th quarter worth approximately $26,000. Ballentine Partners LLC bought a new stake in Absci in the 4th quarter valued at $27,000. BNP Paribas Financial Markets acquired a new position in Absci in the 4th quarter valued at $28,000. Finally, Verdence Capital Advisors LLC acquired a new position in Absci in the 4th quarter valued at $37,000. Institutional investors own 52.05% of the company's stock.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.